[{"id":"c72f3a57-80b1-4204-bf22-b374de81ba27","acronym":"","url":"https://clinicaltrials.gov/study/NCT07114653","created_at":"2025-08-16T14:08:30.041Z","updated_at":"2025-08-16T14:08:30.041Z","phase":"","brief_title":"The Role of POLE Mutation in High Risk Endometrial Cancer.","source_id_and_acronym":"NCT07114653","lead_sponsor":"Far Eastern Memorial Hospital","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-08-11"},{"id":"277ff408-67f7-4d82-ab62-08c41100ac4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07006103","created_at":"2025-06-07T14:39:04.179Z","updated_at":"2025-06-07T14:39:04.179Z","phase":"","brief_title":"PRECISION MEDICINE APPLIED TO THE STUDY OF ENDOMETRIAL CANCER: APPLICATION OF NGS FOR MOLECULAR CLASSIFICATION.","source_id_and_acronym":"NCT07006103","lead_sponsor":"Hospital Italiano de Buenos Aires","biomarkers":" POLE","pipe":"","alterations":" ","tags":["POLE"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-06-05"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"0cde78dd-3c84-4aec-a573-c0c0e01915a1","acronym":"OPTEC","url":"https://clinicaltrials.gov/study/NCT03460483","created_at":"2021-01-18T17:03:29.688Z","updated_at":"2025-02-25T13:48:28.789Z","phase":"","brief_title":"Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care","source_id_and_acronym":"NCT03460483 - OPTEC","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" MSI • POLE","pipe":" | ","alterations":" POLE mutation","tags":["MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1001","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-20"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"dc334b0f-8b5c-4b2f-8468-f243cf63a6a0","acronym":"NCI-2022-09458","url":"https://clinicaltrials.gov/study/NCT05627635","created_at":"2022-11-25T15:58:22.182Z","updated_at":"2025-02-25T15:20:07.740Z","phase":"Phase 1/2","brief_title":"FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05627635 - NCI-2022-09458","lead_sponsor":"City of Hope Medical Center","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 10/07/2025","primary_completion_date":" 10/07/2025","study_txt":" Completion: 10/07/2025","study_completion_date":" 10/07/2025","last_update_posted":"2025-02-12"},{"id":"78d75030-5237-4421-a1d7-2295ec99343b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05156268","created_at":"2021-12-14T12:53:32.808Z","updated_at":"2025-02-25T16:17:02.952Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma","source_id_and_acronym":"NCT05156268","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • MSI • POLE","pipe":" | ","alterations":" TP53 mutation • MSI-H/dMMR","tags":["TP53 • MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/27/2022","start_date":" 01/27/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-04"},{"id":"256df84b-62ee-44dd-bf61-7e052e3333ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02899793","created_at":"2021-01-18T14:13:54.458Z","updated_at":"2025-02-25T16:05:12.956Z","phase":"Phase 2","brief_title":"Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer","source_id_and_acronym":"NCT02899793","lead_sponsor":"Yale University","biomarkers":" MSI • POLE • POLD1","pipe":" | ","alterations":" POLE mutation • POLD1 mutation","tags":["MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation • POLD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-31"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"652d0b54-6a18-4c4d-b642-1b099fb25232","acronym":"","url":"https://clinicaltrials.gov/study/NCT02658279","created_at":"2021-01-18T12:56:53.610Z","updated_at":"2025-02-25T16:04:15.191Z","phase":"","brief_title":"Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype","source_id_and_acronym":"NCT02658279","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSI • POLE • MSH6 • MSH2 • POLD1","pipe":"","alterations":" ","tags":["MSI • POLE • MSH6 • MSH2 • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/22/2016","start_date":" 01/22/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-12-06"},{"id":"36e9c4c3-28f9-471f-91db-41aa4b6178a4","acronym":"RAINBO","url":"https://clinicaltrials.gov/study/NCT05255653","created_at":"2022-02-24T13:52:52.644Z","updated_at":"2025-02-25T15:00:17.741Z","phase":"Phase 2/3","brief_title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","source_id_and_acronym":"NCT05255653 - RAINBO","lead_sponsor":"Leiden University Medical Center","biomarkers":" ER • POLE","pipe":" | ","alterations":" ER positive • MSI-H/dMMR • POLE mutation","tags":["ER • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • MSI-H/dMMR • POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • megestrol • medroxyprogesterone"],"overall_status":"Recruiting","enrollment":" Enrollment 1615","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-11-28"},{"id":"52596305-5825-4a69-9da4-f4d1348c8313","acronym":"","url":"https://clinicaltrials.gov/study/NCT04774419","created_at":"2021-03-01T14:52:30.559Z","updated_at":"2025-02-25T13:19:57.496Z","phase":"Phase 2","brief_title":"Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery","source_id_and_acronym":"NCT04774419","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation","tags":["MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/02/2021","start_date":" 04/02/2021","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-11-11"},{"id":"d7a0703a-8b1b-461b-a082-3de4e2b533f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03061188","created_at":"2021-01-17T18:03:06.477Z","updated_at":"2025-02-25T14:37:19.874Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of Nivolumab \u0026 Veliparib in Patients With Advanced Solid Tumors \u0026 Lymphoma","source_id_and_acronym":"NCT03061188","lead_sponsor":"Northwestern University","biomarkers":" BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC","pipe":" | ","alterations":" MSI-H/dMMR • RAD50 mutation","tags":["BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAD50 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 03/11/2018","primary_completion_date":" 03/11/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2024-06-12"},{"id":"43f66187-5b30-4357-8f5c-84f785cedc80","acronym":"POD1UM-204","url":"https://clinicaltrials.gov/study/NCT04463771","created_at":"2021-01-18T21:27:26.857Z","updated_at":"2024-07-02T16:34:37.736Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","source_id_and_acronym":"NCT04463771 - POD1UM-204","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1 • MSI • POLE","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation","tags":["PD-L1 • MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-06"},{"id":"08ecba68-627d-4239-8ccd-1d8c5c073213","acronym":"POLE-END","url":"https://clinicaltrials.gov/study/NCT06409039","created_at":"2024-05-10T20:31:55.546Z","updated_at":"2024-07-02T16:35:04.467Z","phase":"","brief_title":"POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women \u003e= 18 Years Old, With the Pole Mutation","source_id_and_acronym":"NCT06409039 - POLE-END","lead_sponsor":"Azienda Ulss 2 Marca Trevigiana","biomarkers":" POLE","pipe":"","alterations":" ","tags":["POLE"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 80","initiation":"Initiation: 09/04/2023","start_date":" 09/04/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-10"},{"id":"c67606ea-7796-46a1-9d35-f3d0edacc3ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912572","created_at":"2021-01-18T14:17:54.432Z","updated_at":"2024-07-02T16:35:08.730Z","phase":"Phase 2","brief_title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT02912572","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation • MSH6 expression","tags":["MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-19"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"4d256248-7b1f-42ce-8be5-81d828dd1b6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04457284","created_at":"2021-01-18T21:26:08.974Z","updated_at":"2025-02-25T14:29:24.340Z","phase":"Phase 2","brief_title":"Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer","source_id_and_acronym":"NCT04457284","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • POLE","pipe":" | ","alterations":" MSI-H/dMMR","tags":["BRAF • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • temozolomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-03-11"},{"id":"07c7a5d9-df0c-45c5-9b74-abae8c8d1379","acronym":"","url":"https://clinicaltrials.gov/study/NCT03751761","created_at":"2021-01-18T18:23:38.922Z","updated_at":"2024-07-02T16:35:17.456Z","phase":"Phase 1/2","brief_title":"GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study","source_id_and_acronym":"NCT03751761","lead_sponsor":"Asan Medical Center","biomarkers":" PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation","tags":["PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 06/11/2018","start_date":" 06/11/2018","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 08/30/2023","study_completion_date":" 08/30/2023","last_update_posted":"2024-02-28"},{"id":"9c246bac-2a05-4be1-9b1f-a7e2e819e603","acronym":"AcSé","url":"https://clinicaltrials.gov/study/NCT03012581","created_at":"2021-01-17T17:45:03.399Z","updated_at":"2025-02-25T14:37:06.018Z","phase":"Phase 2","brief_title":"Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types","source_id_and_acronym":"NCT03012581 - AcSé","lead_sponsor":"UNICANCER","biomarkers":" MSI • POLE","pipe":" | ","alterations":" POLE mutation","tags":["MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 269","initiation":"Initiation: 06/16/2017","start_date":" 06/16/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 11/11/2023","study_completion_date":" 11/11/2023","last_update_posted":"2024-02-28"},{"id":"b53740c4-b1e7-41cb-af68-382331f382df","acronym":"","url":"https://clinicaltrials.gov/study/NCT06206083","created_at":"2024-01-16T20:20:19.657Z","updated_at":"2025-02-25T13:13:33.863Z","phase":"","brief_title":"Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis","source_id_and_acronym":"NCT06206083","lead_sponsor":"National Institute of Cancerología","biomarkers":" TP53 • MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" POLE mutation","tags":["TP53 • MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-02-28"},{"id":"714d31fd-dbae-4657-8b18-b135a22032bd","acronym":"PAM","url":"https://clinicaltrials.gov/study/NCT04262089","created_at":"2021-01-18T20:42:38.005Z","updated_at":"2025-02-25T16:09:58.338Z","phase":"Phase 1","brief_title":"Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study","source_id_and_acronym":"NCT04262089 - PAM","lead_sponsor":"University Medical Center Groningen","biomarkers":" POLE","pipe":" | ","alterations":" MSI-H/dMMR","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-12-05"},{"id":"40c5a9dd-b0cf-48c4-bf22-51d4452040b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448718","created_at":"2021-01-18T17:00:17.468Z","updated_at":"2025-02-25T14:58:45.009Z","phase":"Phase 2","brief_title":"Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations","source_id_and_acronym":"NCT03448718","lead_sponsor":"Matthew Galsky","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/17/2018","start_date":" 04/17/2018","primary_txt":" Primary completion: 07/14/2021","primary_completion_date":" 07/14/2021","study_txt":" Completion: 10/15/2021","study_completion_date":" 10/15/2021","last_update_posted":"2023-11-22"},{"id":"8b15a447-d4d1-4420-baea-7de9dddb313a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06118125","created_at":"2023-11-07T20:13:23.197Z","updated_at":"2024-07-02T16:35:30.201Z","phase":"","brief_title":"Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement","source_id_and_acronym":"NCT06118125","lead_sponsor":"University of Bordeaux","biomarkers":" POLE","pipe":"","alterations":" ","tags":["POLE"],"overall_status":"Completed","enrollment":" Enrollment 376","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 09/01/2022","study_completion_date":" 09/01/2022","last_update_posted":"2023-11-06"}]